Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19239046 | 1.00 | MEN1 (0.36) | MEN1KMT2ACES2KDM4EALDH1A1 | |
| SCHEMBL12981321 | 0.90 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26353810 | 0.85 | CES2 (0.42) | MEN1KMT2ACES2ALDH1A1MAPK1 | |
| SCHEMBL25725933 | 0.85 | CES2 (0.42) | MEN1KMT2ACES2ALDH1A1MAPK1 | |
| SCHEMBL18492359 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL18751670 | 0.83 | CES2 (0.43) | KMT2ACES2KDM4EALDH1A1MAPK1 | |
| SCHEMBL20128726 | 0.83 | KDM4E (0.43) | MEN1KMT2ACES2KDM4EALDH1A1 | |
| SCHEMBL4402902 | 0.83 | KDM4E (0.43) | MEN1KMT2ACES2KDM4EALDH1A1 | |
| SCHEMBL27408407 | 0.83 | KDM4E (0.43) | MEN1KMT2ACES2KDM4EALDH1A1 | |
| SCHEMBL20133152 | 0.83 | KDM4E (0.43) | MEN1KMT2ACES2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9908919-B2 | Cyclic apelin derivatives for the treatment of heart failure | NOVARTIS AG (CH) | 2018-03-06 | — | — | US | disclosed |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9683019-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9683018-B2 | Disulfide cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-20160159871-A1 | CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160145309-A1 | DISULFIDE CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-9340582-B2 | Bioconjugates of synthetic apelin polypeptides | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-9266925-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150284446-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-10-08 | — | — | US | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284446-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | APLNR, AP3B1, FABP3 | MEN1 1792/4885KMT2A 3388/4885CES2 4817/4885 |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | MEN1 4611/4885KMT2A 4870/4885CES2 3021/4885 |
| US-20160145309-A1 | DISULFIDE CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | ACKR3, APLNR, NPY1R | MEN1 4761/4885KMT2A 4875/4885CES2 3179/4885 |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | MEN1 4611/4885KMT2A 4870/4885CES2 3021/4885 |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | MEN1 3343/4885KMT2A 4837/4885CES2 3781/4885 |
| US-20160159871-A1 | CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE | APLNR, ACKR3, NPBWR1 | MEN1 4382/4885KMT2A 4852/4885CES2 3671/4885 |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | MEN1 4611/4885KMT2A 4870/4885CES2 3021/4885 |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | MEN1 3343/4885KMT2A 4837/4885CES2 3781/4885 |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | APLNR, AP3B1, FABP3 | MEN1 1792/4885KMT2A 3388/4885CES2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.